Georgia-Based Airway Therapeutics Raises $50M in Funding Round

Airway Therapeutics, an Atlanta, GA-based clinical biopharmaceutical company developing new biologic therapies for respiratory, inflammatory, and infectious diseases, has raised $50 million in a funding round.

The funding was backed by Cincinnati Children’s and a syndicate of large family offices.

The financing includes $26 million previously raised through a SAFE financing and $24 million through its Series E-2 round.

The company plans to use the capital primarily to advance its lead candidate, zelpultide alfa, in a late-stage clinical trial for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants.

Funding Snapshot

About Airway Therapeutics

Airway Therapeutics is a late-stage clinical biopharmaceutical company developing biologic therapies for respiratory, inflammatory, and infectious diseases.

The company's lead candidate, zelpultide alfa, is being developed to prevent bronchopulmonary dysplasia in very preterm infants. BPD is a serious chronic lung condition that can affect babies born extremely prematurely.

Read More:AI Startup Standard Metrics Raises $20M in Series B Funding

Airway Therapeutics is focused on developing therapies for serious respiratory diseases where significant unmet medical need's remain.

Core areas include:

• Respiratory disease therapies
• Infectious disease therapies
• Biologic drug development
• Neonatal respiratory care

Core Technologies / Products / Services